Skip to content

Clinical Efficacy Observation of Ultrasound-Guided Shoulder Joint Hydrodilation with Different Capacities for the Treatment of Frozen Shoulder: A Randomized Controlled Trial

Clinical Efficacy Observation of Ultrasound-Guided Shoulder Joint Hydrodilation with Different Capacities for the Treatment of Frozen Shoulder: A Randomized Controlled Trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092627
Enrollment
Unknown
Registered
2024-11-20
Start date
2024-11-20
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

frozen shoulder

Interventions

Group A(simple injection):Intra-articular injection of the shoulder joint with 1ml of compound betamethasone + 1.5ml of 2% lidocaine + 2.5ml of saline solution.
Group B(10ml Hydrodilation):Intra-articular injection of the shoulder joint with 1ml of compound betamethasone, 3ml of 2% lidocaine, and 6ml of saline solution.
Group C(20 ml Hydrodilation):Intra-articular injection of the shoulder joint with 1ml of compound betamethasone, 6ml of 2% lidocaine, and 13ml of saline solution.

Sponsors

Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. The presence of symptoms of unilateral shoulder stiffness accompanied by pain for at least one month; 2. Active range of motion is restricted by more than 30° in at least two planes compared to the contralateral side or normal values; 3. Age is 40 years or older (including 40 years).

Exclusion criteria

Exclusion criteria: 1. A history of severe shoulder trauma (such as dislocation, fracture, or full-thickness tear requiring surgery); 2. A history of previous shoulder joint surgery; 3. Received shoulder joint injection treatment within the past 3 months; 4. Systemic inflammatory diseases (such as rheumatoid arthritis and osteoarthritis, etc.); 5. Concurrent pregnancy, infection, mental disorders, severe cardiovascular and cerebrovascular diseases, liver and kidney failure; 6. Abnormal coagulation function and allergy to the drugs used.

Design outcomes

Primary

MeasureTime frame
Scoring of shoulder pain and disability index;

Secondary

MeasureTime frame
The numerical value of the digital rating scale;Numerical value of active range of motion of shoulder joint;

Countries

China

Contacts

Public ContactYin Qin

Department of pain, Affiliated Hospital of Xuzhou Medical University

1915992218@qq.com+86 177 1826 0192

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026